1. Home
  2. SUI vs VTRS Comparison

SUI vs VTRS Comparison

Compare SUI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SUI

Sun Communities Inc.

HOLD

Current Price

$129.25

Market Cap

16.9B

Sector

Real Estate

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.47

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SUI
VTRS
Founded
1975
1961
Country
United States
United States
Employees
N/A
30000
Industry
Real Estate Investment Trusts
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.9B
17.2B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
SUI
VTRS
Price
$129.25
$13.47
Analyst Decision
Buy
Buy
Analyst Count
15
4
Target Price
$141.20
$13.50
AVG Volume (30 Days)
653.8K
7.8M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
3.48%
3.53%
EPS Growth
1426.76
N/A
EPS
10.84
N/A
Revenue
$2,306,100,000.00
$14,299,900,000.00
Revenue This Year
$5.24
$4.41
Revenue Next Year
$5.08
$1.96
P/E Ratio
$11.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$115.53
$7.34
52 Week High
$137.85
$16.47

Technical Indicators

Market Signals
Indicator
SUI
VTRS
Relative Strength Index (RSI) 48.62 45.81
Support Level $124.43 $12.90
Resistance Level $130.13 $13.63
Average True Range (ATR) 2.42 0.30
MACD 0.06 0.06
Stochastic Oscillator 63.57 65.03

Price Performance

Historical Comparison
SUI
VTRS

About SUI Sun Communities Inc.

Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: